Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study

BACKGROUND: Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at studying the efficacy and safety of Paxlovid in hospitalized adult patients with SARS-Cov-2 (Omicron BA.2.2 variant) infection and severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiao, Pan, Xiaojun, Zhang, Sheng, Li, Ming, Ma, Ke, Fan, Cunyi, Lv, Ying, Guan, Xiangdong, Yang, Yi, Ye, Xiaofei, Deng, Xingqi, Wang, Yunfeng, Qin, LunXiu, Xia, Zhijie, Ge, Zi, Zhou, Quanhong, Zhang, Xian, Ling, Yun, Qi, Tangkai, Wen, Zhenliang, Huang, Sisi, Zhang, Lidi, Wang, Tao, Liu, Yongan, Huang, Yanxia, Li, Wenzhe, Du, Hangxiang, Chen, Yizhu, Xu, Yan, Zhao, Qiang, Zhao, Ren, Annane, Djillali, Qu, Jieming, Chen, Dechang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899586/
https://www.ncbi.nlm.nih.gov/pubmed/36777445
http://dx.doi.org/10.1016/j.lanwpc.2023.100694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899586/
https://www.ncbi.nlm.nih.gov/pubmed/36777445
http://dx.doi.org/10.1016/j.lanwpc.2023.100694

Ejemplares similares